跳至主要内容
临床试验/NCT01415414
NCT01415414已完成不适用

The Image Quality and Radiation Dose of CECT With Ultravist® in Patients With Abdominal Pelvic Disease - INDEX

Bayer0 个研究点目标入组 11,660 人开始时间: 2011年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Bayer
入组人数
11,660
主要终点
Image quality evaluated by calculated CNR (Contrast to Noise Ratio)

研究概览

简要总结

It is a prospective, non-interventional, multi-center study. The primary objective of this study is to evaluate the image quality of Ultravist in patients requiring contrast-enhanced CT considering the routine use in patient population's, region's indication.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients undergoing contrast enhanced CT Imaging with Ultravist (iopromide) in abdomen or pelvis.

排除标准

  • There is no other exclusion criteria beyond the contraindications contained in the Summary of Product Characteristics

研究组 & 干预措施

Group 1

干预措施: Iopromide (Ultravist, BAY86-4877) (Drug)

结局指标

主要结局

Image quality evaluated by calculated CNR (Contrast to Noise Ratio)

时间窗: 1 day

次要结局

  • Image quality evaluated by calculated SNR (Signal Noise Ratio)(1 day)
  • Radiation dose (CTDIvol)(1 day)
  • Descriptive analysis of contrast medial injection protocol(1 day)

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

相似试验